Cardiff Oncology (CRDF) EBITDA Margin Growth (5y) (2016 - 2026)
Cardiff Oncology (CRDF) EBITDA Margin Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88,569.00 |
| Dec 31, 2025 | 223,868.00 |
| Sep 30, 2025 | -677,025.00 |
| Jun 30, 2025 | -267,286.00 |
| Mar 31, 2025 | -712,979.00 |
| Dec 31, 2024 | -376,624.00 |
| Sep 30, 2024 | 50,333.00 |
| Jun 30, 2024 | 375,478.00 |
| Mar 31, 2024 | 105,461.00 |
| Dec 31, 2023 | -136,321.00 |
| Sep 30, 2023 | -331,063.00 |
| Jun 30, 2023 | -733,315.00 |
| Mar 31, 2023 | -503,109.00 |
| Dec 31, 2022 | -529,194.00 |
| Sep 30, 2022 | 19,353.00 |
| Jun 30, 2022 | -570,365.00 |
| Mar 31, 2022 | 41,758.00 |
| Dec 31, 2021 | 722,323.00 |
| Sep 30, 2021 | 301,390.00 |
| Jun 30, 2021 | -53,449.00 |